Posted on 09/20/2024 7:51:41 PM PDT by ConservativeMind
A small clinical trial suggests that a duo of drugs can extend survival for people battling advanced kidney cancer.
Researchers developed the new regimen, a combination of pazopanib (Votrient) and bevacizumab (Avastin).
Pazopanib is from a class of cancer drugs known as tyrosine kinase inhibitors (TKIs). These drugs work by blocking vascular endothelial growth factor (VEGF) signaling—a key mechanism that cancer cells need to grow.
In prior trials that led to pazopanib's approval by the U.S. FDA, the drug led to an average survival (without cancer progression) of just over 11 months among people diagnosed with kidney tumors.
The new trial, which involved 51 patients, found that combining pazopanib treatment with bevacizumab doubled that progression-free survival, to more than 23 months, on average.
Patients received pazopanib and bevacizumab in 10-week treatment cycles.
They first underwent treatment with pazopanib during days one to 28.
As a team led by Dr. Saby George explained, pazopanib works by shutting down VEGF, but any increase in VEGF can lead to cancer cell resistance against the drug.
So, patients got bevacizumab midway through the 10-week cycle (days 36 to 50), since that drug "neutralizes" VEGF—potentially extending pazopanib's cancer-fighting power.
The strategy appears to have worked, greatly boosting survival among those patients who received it.
Some patients with advanced kidney cancers were good candidates for powerful immunotherapy cancer medicines, but George's team noted that pazopanib/bevacizumab might be a safer option for some.
The combo drug therapy had "superior safety compared with immunotherapy combinations," the researchers noted.
"Because immunotherapy options were available to patients in other risk groups, the Phase II group included more patients in the Favorable Risk category," said George. "The encouraging results suggest that alternating pazopanib with bevacizumab is a promising treatment regimen for renal cell [kidney] carcinoma patients in the Favorable Risk group."
(Excerpt) Read more at medicalxpress.com ...
These were found to be safer than immunotherapy options.
Ivermectin is a anti cancer drug, not horse paste.
Bookmark
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.